mrcc: identifying and managing aes in tkis and io therapy
Published 5 years ago • 193 plays • Length 7:55Download video MP4
Download video MP3
Similar videos
-
9:05
mrcc: when is tki/i-o combination therapy appropriate?
-
6:56
role of tkis in intermediate or poor-risk mrcc
-
3:15
tki/i-o therapy in mrcc
-
7:43
mrcc: resistance to vegf and i/o
-
3:36
real-world outcomes of io & tkis in mrcc
-
6:40
evaluating i-o monotherapy’s value in treating mrcc
-
4:27
vegf-tki therapy in first-line mrcc
-
1:08
dr hajj chehade on potential risk factors for irae development in mrcc
-
5:10
therapeutic sequencing in mrcc
-
10:38
considerations for using adjuvant therapy in mrcc
-
10:15
novel combinations in mrcc: axi/pembro vs axi/avelumab
-
3:25
combination therapies to overcome resistance in mrcc
-
0:46
dr. ho on first-line tki monotherapy in mrcc
-
5:38
management of parp inhibitor aes in ovarian cancer
-
2:44
impassion130: addressing immune-related aes in tnbc management
-
8:40
favorable-risk mrcc: choosing appropriate frontline therapy
-
2:01
managing aes in metastatic cspc: tropic and card trials
-
2:23
the future of tyrosine kinase inhibitors for melanoma and open questions
-
6:36
case study: utilizing multiple therapies in mrcc